Cited 2 times in
Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 류철형 | - |
dc.contributor.author | 조한나 | - |
dc.date.accessioned | 2024-12-06T03:03:35Z | - |
dc.date.available | 2024-12-06T03:03:35Z | - |
dc.date.issued | 2024-09 | - |
dc.identifier.issn | 0364-5134 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/200964 | - |
dc.description.abstract | ObjectiveWe compared the accuracy of amyloid and [18F]Flortaucipir (FTP) tau positron emission tomography (PET) visual reads for distinguishing patients with mild cognitive impairment (MCI) or dementia with fluid biomarker support of Alzheimer's disease (AD).MethodsParticipants with FTP-PET, amyloid-PET, and diagnosis of dementia-AD (n = 102), MCI-AD (n = 41), non-AD diseases (n = 76), and controls (n = 20) were included. AD status was determined independent of PET by cerebrospinal fluid or plasma biomarkers. The mean age was 66.9 years, and 44.8% were women. Three readers interpreted scans blindly and independently. Amyloid-PET was classified as positive/negative using tracer-specific criteria. FTP-PET was classified as positive with medial temporal lobe (MTL) binding as the minimum uptake indicating AD tau (tau-MTL+), positive with posterolateral temporal or extratemporal cortical binding in an AD-like pattern (tau-CTX+), or negative. The majority of scan interpretations were used to calculate diagnostic accuracy of visual reads in detecting MCI/dementia with fluid biomarker support for AD (MCI/dementia-AD).ResultsSensitivity of amyloid-PET for MCI/dementia-AD was 95.8% (95% confidence interval 91.1-98.4%), which was comparable to tau-CTX+ 92.3% (86.7-96.1%, p = 0.67) and tau-MTL+ 97.2% (93.0-99.2%, p = 0.27). Specificity of amyloid-PET for biomarker-negative healthy and disease controls was 84.4% (75.5-91.0%), which was like tau-CTX+ 88.5% (80.4-94.1%, p = 0.34), and trended toward being higher than tau-MTL+ 75.0% (65.1-83.3%, p = 0.08). Tau-CTX+ had higher specificity than tau-MTL+ (p = 0.0002), but sensitivity was lower (p = 0.02), driven by decreased sensitivity for MCI-AD (80.5% [65.1-91.2] vs. 95.1% [83.5-99.4], p = 0.03).InterpretationAmyloid- and tau-PET visual reads have similar sensitivity/specificity for detecting AD in cognitively impaired patients. Visual tau-PET interpretations requiring cortical binding outside MTL increase specificity, but lower sensitivity for MCI-AD. ANN NEUROL 2024,Accuracy of diagnosing Alzheimer's disease (AD) is compared between amyloid-PET visual reads and tau-PET visual reads with either medial temporal lobe binding (tau-MTL+) or with posterolateral temporal or extra-temporal cortical binding (tau-CTX+) as the minimum threshold for an AD tau positive scan. Amyloid- and tau-PET visual reads have similar sensitivity and specificity for detecting AD in cognitively impaired participants. Tau-CTX+ increases specificity for AD, but with significant loss of sensitivity for mild cognitive impairment due to AD (MCI-AD). Tau-MTL+ increases sensitivity for AD, but there is lower specificity for MCI-AD. image, | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Liss | - |
dc.relation.isPartOf | ANNALS OF NEUROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Alzheimer Disease* / diagnosis | - |
dc.subject.MESH | Alzheimer Disease* / diagnostic imaging | - |
dc.subject.MESH | Alzheimer Disease* / metabolism | - |
dc.subject.MESH | Amyloid beta-Peptides / metabolism | - |
dc.subject.MESH | Biomarkers / blood | - |
dc.subject.MESH | Carbolines | - |
dc.subject.MESH | Cognitive Dysfunction* / diagnosis | - |
dc.subject.MESH | Cognitive Dysfunction* / diagnostic imaging | - |
dc.subject.MESH | Diagnosis, Differential | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neurodegenerative Diseases / diagnosis | - |
dc.subject.MESH | Neurodegenerative Diseases / diagnostic imaging | - |
dc.subject.MESH | Positron-Emission Tomography* / methods | - |
dc.subject.MESH | tau Proteins* / cerebrospinal fluid | - |
dc.title | Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학교실) | - |
dc.contributor.googleauthor | David N Soleimani-Meigooni | - |
dc.contributor.googleauthor | Ruben Smith | - |
dc.contributor.googleauthor | Karine Provost | - |
dc.contributor.googleauthor | Orit H Lesman-Segev | - |
dc.contributor.googleauthor | Isabel Elaine Allen | - |
dc.contributor.googleauthor | Miranda K Chen | - |
dc.contributor.googleauthor | Hanna Cho | - |
dc.contributor.googleauthor | Lauren Edwards | - |
dc.contributor.googleauthor | Shorena Janelidze | - |
dc.contributor.googleauthor | Renaud La Joie | - |
dc.contributor.googleauthor | Nidhi Mundada | - |
dc.contributor.googleauthor | Rik Ossenkoppele | - |
dc.contributor.googleauthor | Erik Stomrud | - |
dc.contributor.googleauthor | Olof Strandberg | - |
dc.contributor.googleauthor | Amelia Strom | - |
dc.contributor.googleauthor | Adam L Boxer | - |
dc.contributor.googleauthor | Jeffrey L Dage | - |
dc.contributor.googleauthor | Maria Luisa Gorno-Tempini | - |
dc.contributor.googleauthor | Joel H Kramer | - |
dc.contributor.googleauthor | Bruce L Miller | - |
dc.contributor.googleauthor | Julio C Rojas | - |
dc.contributor.googleauthor | Howard J Rosen | - |
dc.contributor.googleauthor | Chul H Lyoo | - |
dc.contributor.googleauthor | Oskar Hansson | - |
dc.contributor.googleauthor | Gil D Rabinovici | - |
dc.identifier.doi | 10.1002/ana.27008 | - |
dc.contributor.localId | A01333 | - |
dc.contributor.localId | A03920 | - |
dc.relation.journalcode | J00166 | - |
dc.identifier.eissn | 1531-8249 | - |
dc.identifier.pmid | 38888212 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/ana.27008 | - |
dc.contributor.alternativeName | Lyoo, Chul Hyoung | - |
dc.contributor.affiliatedAuthor | 류철형 | - |
dc.contributor.affiliatedAuthor | 조한나 | - |
dc.citation.volume | 96 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 476 | - |
dc.citation.endPage | 487 | - |
dc.identifier.bibliographicCitation | ANNALS OF NEUROLOGY, Vol.96(3) : 476-487, 2024-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.